Finance Watch: Biopharma Fundraising Impact Expected, But Not Apparent Yet

While COVID-19 shocked global financial markets and is expected to impact biopharma fundraising, investment in drug developers continues, including through two new venture capital funds totaling nearly $2bn. Also, Coherus issues debt to fund deals and MOMA launches with $86m in VC cash.

Venture capital fundraising by biopharmaceutical companies totaled $5.7bn during the first quarter of 2020 – the second-highest amount ever raised by the industry in a single quarter – as private drug developers finalized financings that most likely were in the works before the COVID-19 pandemic shrank the values of publicly traded companies.

Biopharma venture capital investment is sure to feel an impact over the course of 2020 as investors hold on to...